How CD95 stimulates invasion

Cell Cycle

Volumn 10, Issue 22, 2011, Pages 3857-3862

  Steller, Ernst J A ^a   Borel Rinkes, Inne H M ^a   Kranenburg, Onno ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

c Src; Caspase 8; CD95; Cofilin; Colorectal; Invasion; Metastasis; Migration; Neutrophil; NF B; PI3K; Platelet derived growth factor receptor; Rac

Indexed keywords

ACTIN; CYTOSKELETON PROTEIN; FAS LIGAND; INTEGRIN; METALLOPROTEINASE; PROTEIN TYROSINE KINASE; RAC PROTEIN;

CELL INVASION; CELL MIGRATION; ENZYME ACTIVITY; FOCAL ADHESION; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION;

EID: 81855189615     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.10.22.18290     Document Type: Review

References (64)

1. Takahashi T, Tanaka M, Brannan CI, Jenkins NA, Copeland NG, Suda T, et al. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 1994; 76:969-76; PMID:7511063; DOI:10.1016/0092-8674(94) 90375-1.
2. Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 1992; 356:314-7; PMID:1372394; DOI:10.1038/356314a0.
3. Fisher GH, Rosenberg FJ, Straus SE, Dale JK, Middleton LA, Lin AY, et al. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 1995; 81:935-46; PMID:7540117; DOI:10.1016/0092-8674(95)90013-6.
4. Rieux-Laucat F, Le DF, Hivroz C, Roberts IA, Debatin KM, Fischer A, et al. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 1995; 268:1347-9; PMID:7539157; DOI:10.1126/science. 7539157.
5. Peter ME, Budd RC, Desbarats J, Hedrick SM, Hueber AO, Newell MK, et al. The CD95 receptor: apoptosis revisited. Cell 2007; 129:447-50; PMID:17482535; DOI:10.1016/j.cell.2007.04.031.
6. Allison J, Georgiou HM, Strasser A, Vaux DL. Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts. Proc Natl Acad Sci USA 1997; 94:3943-7; PMID:9108084; DOI:10.1073/pnas.94.8.3943.
7. Kang SM, Schneider DB, Lin Z, Hanahan D, Dichek DA, Stock PG, et al. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nat Med 1997; 3:738-43; PMID:9212099; DOI:10.1038/nm0797-738.
8. Seino K, Kayagaki N, Okumura K, Yagita H. Antitumor effect of locally produced CD95 ligand. Nat Med 1997; 3:165-70; PMID:9018234; DOI:10.1038/nm0297- 165.
9. Seino K, Iwabuchi K, Kayagaki N, Miyata R, Nagaoka I, Matsuzawa A, et al. Chemotactic activity of soluble Fas ligand against phagocytes. J Immunol 1998; 161:4484-8; PMID:9794371.
10. Jarad G, Wang B, Khan S, DeVore J, Miao H, Wu K, et al. Fas activation induces renal tubular epithelial cell beta8 integrin expression and function in the absence of apoptosis. J Biol Chem 2002; 277:47826-33; PMID:12324452; DOI:10.1074/jbc.M204901200.
11. Barnhart BC, Legembre P, Pietras E, Bubici C, Franzoso G, Peter ME. CD95 ligand induces motility and invasiveness of apoptosis-resistant tumor cells. EMBO J 2004; 23:3175-85; PMID:15272306; DOI:10.1038/sj.emboj.7600325.
12. Hoogwater FJ, Nijkamp MW, Smakman N, Steller EJ, Emmink BL, Westendorp BF, et al. Oncogenic K-Ras turns death receptors into metastasis-promoting receptors in human and mouse colorectal cancer cells. Gastroenterology 2010; 138:2357-67; PMID:20188103; DOI:10.1053/j.gastro.2010.02.046.
13. Kleber S, Sancho-Martinez I, Wiestler B, Beisel A, Gieffers C, Hill O, et al. Yes and PI3K bind CD95 to signal invasion of glioblastoma. Cancer Cell 2008; 13:235-48; PMID:18328427; DOI:10.1016/j.ccr.2008.02.003.
14. Nijkamp MW, Hoogwater FJ, Steller EJ, Westendorp BF, van der Meulen TA, Leenders MW, et al. CD95 is a key mediator of invasion and accelerated outgrowth of mouse colorectal liver metastases following radiofrequency ablation. J Hepatol 2010; 53:1069-77; PMID:20832890; DOI:10.1016/j.jhep.2010.04.040.
15. Kayagaki N, Kawasaki A, Ebata T, Ohmoto H, Ikeda S, Inoue S, et al. Metalloproteinase-mediated release of human Fas ligand. J Exp Med 1995; 182:1777-83; PMID:7500022; DOI:10.1084/jem.182.6.1777.
16. Tanaka M, Suda T, Takahashi T, Nagata S. Expression of the functional soluble form of human fas ligand in activated lymphocytes. EMBO J 1995; 14:1129-35; PMID:7536672.
17. O'Reilly LA, Tai L, Lee L, Kruse EA, Grabow S, Fairlie WD, et al. Membrane-bound Fas ligand only is essential for Fas-induced apoptosis. Nature 2009; 461:659-63; PMID:19794494; DOI:10.1038/nature08402.
18. Tauzin S, Chaigne-Delalande B, Selva E, Khadra N, Daburon S, Contin-Bordes C, et al. The Naturally Processed CD95L Elicits a c-Yes/Calcium/PI3KDriven Cell Migration Pathway. PLoS Biol 2011; 9:1001090; PMID:21713032; DOI:10.1371/journal.pbio.1001090.
19. Lai YJ, Lin VT, Zheng Y, Benveniste EN, Lin FT. The adaptor protein TRIP6 antagonizes Fas-induced apoptosis but promotes its effect on cell migration. Mol Cell Biol 2010; 30:5582-96; PMID:20876301; DOI:10.1128/MCB.00134-10.
20. Ruan W, Lee CT, Desbarats J. A novel juxtamembrane domain in tumor necrosis factor receptor superfamily molecules activates Rac1 and controls neurite growth. Mol Biol Cell 2008; 19:3192-202; PMID:18508927; DOI:10.1091/mbc.E08-02-0161.
21. Letellier E, Kumar S, Sancho-Martinez I, Krauth S, Funke-Kaiser A, Laudenklos S, et al. CD95-ligand on peripheral myeloid cells activates Syk kinase to trigger their recruitment to the inflammatory site. Immunity 2010; 32:240-52; PMID:20153221; DOI:10.1016/j.immuni.2010.01.011.
22. Steller EJ, Ritsma L, Raats DA, Hoogwater FJ, Emmink BL, Govaert KM, et al. The death receptor CD95 activates the cofilin pathway to stimulate tumour cell invasion. EMBO Rep 2011; 12:931-7; PMID:21760611; DOI:10.1038/embor.2011. 129.
23. Atkinson EA, Ostergaard H, Kane K, Pinkoski MJ, Caputo A, Olszowy MW, et al. A physical interaction between the cell death protein Fas and the tyrosine kinase p59fynT. J Biol Chem 1996; 271:5968-71; PMID:8626376; DOI:10.1074/jbc.271.11.5968.
24. Schlottmann KE, Gulbins E, Lau SM, Coggeshall KM. Activation of Src-family tyrosine kinases during Fas-induced apoptosis. J Leukoc Biol 1996; 60:546-54; PMID:8864141.
25. Daigle I, Yousefi S, Colonna M, Green DR, Simon HU. Death receptors bind SHP-1 and block cytokine-induced anti-apoptotic signaling in neutrophils. Nat Med 2002; 8:61-7; PMID:11786908; DOI:10.1038/nm0102-61.
26. Sancho-Martinez I, Martin-Villalba A. Tyrosine phosphorylation and CD95: a FAScinating switch. Cell Cycle 2009; 8:838-42; PMID:19221505; DOI:10.4161/cc.8.6.7906.
27. Reinehr R, Sommerfeld A, Haussinger D. CD95 ligand is a proliferative and antiapoptotic signal in quiescent hepatic stellate cells. Gastroenterology 2008; 134:1494-506; PMID:18471522; DOI:10.1053/j.gastro.2008.02.021.
28. Cursi S, Rufini A, Stagni V, Condo I, Matafora V, Bachi A, et al. Src kinase phosphorylates Caspase-8 on Tyr380: a novel mechanism of apoptosis suppression. EMBO J 2006; 25:1895-905; PMID:16619028; DOI:10.1038/sj.emboj. 7601085.
29. Gulbins E, Hermisson M, Brenner B, Grassme HU, Linderkamp O, Dichgans J, et al. Cellular stimulation via CD95 involves activation of phosphoinositide- 3-kinase. Pflugers Arch 1998; 435:546-54; PMID:9446703; DOI:10.1007/ s004240050551.
30. Stupack DG. Caspase-8 as a therapeutic target in cancer. Cancer Lett 2010; In press; PMID:20817393; DOI:10.1016/j.canlet.2010.07.022.
31. Barbero S, Barila D, Mielgo A, Stagni V, Clair K, Stupack D. Identification of a critical tyrosine residue in caspase 8 that promotes cell migration. J Biol Chem 2008; 283:13031-4; PMID:18216014; DOI:10.1074/jbc. M800549200.
32. Finlay D, Howes A, Vuori K. Critical role for caspase-8 in epidermal growth factor signaling. Cancer Res 2009; 69:5023-9; PMID:19470771; DOI:10.1158/0008-5472.CAN-08-3731.
33. Senft J, Helfer B, Frisch SM. Caspase-8 interacts with the p85 subunit of phosphatidylinositol-3-kinase to regulate cell adhesion and motility. Cancer Res 2007; 67:11505-9; PMID:18089778; DOI:10.1158/0008-5472.CAN-07-5755.
34. Schmidt-Kittler O, Zhu J, Yang J, Liu G, Hendricks W, Lengauer C, et al. PI3Kalpha inhibitors that inhibit metastasis. Oncotarget 2010; 1:339-48; PMID:21179398.
35. Zawel L. P3Kalpha: a driver of tumor metastasis? Oncotarget 2010; 1:315-6; PMID:21307397.
36. Fresno Vara JA, Casado E, de CJ, Cejas P, Belda-Iniesta C, Gonzalez-Baron M. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 2004; 30:193-204; PMID:15023437.
37. Kim D, Kim S, Koh H, Yoon SO, Chung AS, Cho KS, et al. Akt/PKB promotes cancer cell invasion via increased motility and metalloproteinase production. FASEB J 2001; 15:1953-62; PMID:11532975; DOI:10.1096/fj.01-0198com.
38. Naugler WE, Karin M. NFkappaB and cancer-identifying targets and mechanisms. Curr Opin Genet Dev 2008; 18:19-26; PMID:18440219; DOI:10.1016/j.gde.2008.01.020.
39. Legembre P, Barnhart BC, Peter ME. The relevance of NFkappaB for CD95 signaling in tumor cells. Cell Cycle 2004; 3:1235-9; PMID:15467462; DOI:10.4161/cc.3.10.1194.
40. Kreuz S, Siegmund D, Rumpf JJ, Samel D, Leverkus M, Janssen O, et al. NFkappaB activation by Fas is mediated through FADD, caspase-8 and RIP and is inhibited by FLIP. J Cell Biol 2004; 166:369-80; PMID:15289496; DOI:10.1083/jcb.200401036.
41. Maelfait J, Beyaert R. Non-apoptotic functions of caspase-8. Biochem Pharmacol 2008; 76:1365-73; PMID:18761323; DOI:10.1016/j.bcp.2008.07.034.
42. Trauzold A, Roder C, Sipos B, Karsten K, Arlt A, Jiang P, et al. CD95 and TRAF2 promote invasiveness of pancreatic cancer cells. FASEB J 2005; 19:620-2; PMID:15670977.
43. Geserick P, Hupe M, Moulin M, Leverkus M. RIP-in CD95-induced cell death: The control of alternative death receptors pathways by cIAPs. Cell Cycle 2010; 9:2689-91; PMID:20581447; DOI:10.4161/cc.9.14.12379.
44. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995; 378:785-9; PMID:8524413; DOI:10.1038/378785a0.
45. Neth P, Ciccarella M, Egea V, Hoelters J, Jochum M, Ries C. Wnt signaling regulates the invasion capacity of human mesenchymal stem cells. Stem Cells 2006; 24:1892-903; PMID:16690780; DOI:10.1634/stemcells.2005-0503.
46. Wu B, Crampton SP, Hughes CC. Wnt signaling induces matrix metalloproteinase expression and regulates T cell transmigration. Immunity 2007; 26:227-39; PMID:17306568; DOI:10.1016/j.immuni.2006.12.007.
47. Reuben PM, Cheung HS. Regulation of matrix metalloproteinase (MMP) gene expression by protein kinases. Front Biosci 2006; 11:1199-215; PMID:16368506; DOI:10.2741/1873.
48. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010; 141:52-67; PMID:20371345; DOI:10.1016/j.cell.2010.03.015.
49. McMahon B, Kwaan HC. The plasminogen activator system and cancer. Pathophysiol Haemost Thromb 2008; 36:184-94; PMID:19176991; DOI:10.1159/ 000175156.
50. Zuliani C, Kleber S, Klussmann S, Wenger T, Kenzelmann M, Schreglmann N, et al. Control of neuronal branching by the death receptor CD95 (Fas/Apo-1). Cell Death Differ 2006; 13:31-40; PMID:16003386; DOI:10.1038/sj.cdd.4401720.
51. Desbarats J, Birge RB, Mimouni-Rongy M, Weinstein DE, Palerme JS, Newell MK. Fas engagement induces neurite growth through ERK activation and p35 upregulation. Nat Cell Biol 2003; 5:118-25; PMID:12545171; DOI:10.1038/ncb916.
52. von Philipsborn A, Bastmeyer M. Mechanisms of gradient detection: a comparison of axon pathfinding with eukaryotic cell migration. Int Rev Cytol 2007; 263:1-62; PMID:17725964; DOI:10.1016/S0074-7696(07)63001-0.
53. Rivard N. Phosphatidylinositol-3-kinase: a key regulator in adherens junction formation and function. Front Biosci 2009; 14:510-22; PMID:19273082; DOI:10.2741/3259.
54. Hall A. Rho GTPases and the control of cell behaviour. Biochem Soc Trans 2005; 33:891-5; PMID:16246005; DOI:10.1042/BST20050891.
55. Takahashi K, Sasaki T, Mammoto A, Takaishi K, Kameyama T, Tsukita S, et al. Direct interaction of the Rho GDP dissociation inhibitor with ezrin/radixin/moesin initiates the activation of the Rho small G protein. J Biol Chem 1997; 272:23371-5; PMID:9287351; DOI:10.1074/jbc.272.37.23371.
56. Derivery E, Gautreau A. Generation of branched actin networks: assembly and regulation of the N-WASP and WAVE molecular machines. Bioessays 2010; 32:119-31; PMID:20091750; DOI:10.1002/bies.200900123.
57. Le Clainche C, Carlier MF. Regulation of actin assembly associated with protrusion and adhesion in cell migration. Physiol Rev 2008; 88:489-513; PMID:18391171; DOI:10.1152/physrev.00021.2007.
58. van Rheenen J, Condeelis J, Glogauer M. A common cofilin activity cycle in invasive tumor cells and inflammatory cells. J Cell Sci 2009; 122:305-11; PMID:19158339; DOI:10.1242/jcs.031146.
59. van Rheenen J, Song X, van Roosmalen W, Cammer M, Chen X, Desmarais V, et al. EGF-induced PIP2 hydrolysis releases and activates cofilin locally in carcinoma cells. J Cell Biol 2007; 179:1247-59; PMID:18086920; DOI:10.1083/jcb.200706206.
60. Lai YJ, Chen CS, Lin WC, Lin FT. c-Src-mediated phosphorylation of TRIP6 regulates its function in lysophosphatidic acid-induced cell migration. Mol Cell Biol 2005; 25:5859-68; PMID:15988003; DOI:10.1128/MCB.25.14.5859-68.2005.
61. Takizawa N, Smith TC, Nebl T, Crowley JL, Palmieri SJ, Lifshitz LM, et al. Supervillin modulation of focal adhesions involving TRIP6/ZRP-1. J Cell Biol 2006; 174:447-58; PMID:16880273; DOI:10.1083/jcb.200512051.
62. Barbero S, Mielgo A, Torres V, Teitz T, Shields DJ, Mikolon D, et al. Caspase-8 association with the focal adhesion complex promotes tumor cell migration and metastasis. Cancer Res 2009; 69:3755-63; PMID:19383910; DOI:10.1158/0008-5472.CAN-08-3937.
63. Helfer B, Boswell BC, Finlay D, Cipres A, Vuori K, Bong KT, et al. Caspase-8 promotes cell motility and calpain activity under nonapoptotic conditions. Cancer Res 2006; 66:4273-8; PMID:16618751; DOI:10.1158/0008-5472. CAN-05-4183.
64. Long EO. ICAM-1: getting a grip on leukocyte adhesion. J Immunol 2011; 186:5021-3; PMID:21505213; DOI:10.4049/jimmunol.1100646.